Evidence map›Paper›PMID 32658072›Full record

ArticlePancreas2020

Medullary Pancreatic Carcinoma Due to Somatic POLE Mutation: A Distinctive Pancreatic Carcinoma With Marked Long-Term Survival.

Valentyna Kryklyva, Esther Ter Linden, Leonie I Kroeze, Richarda M de Voer, B Marion van der Kolk, Martijn W J Stommel, John J Hermans, Claudio Luchini, Laura D Wood, Ralph H Hruban and 3 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Pancreas, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. The Dual Role of Necroptosis in Pancreatic Ductal Adenocarcinoma.International journal of molecular sciences · 2023
    Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. The pancreatic cancer genome revisited.Nature reviews. Gastroenterology & hepatology · 2021
    Review
  11. Review
  12. BenignWorld journal of gastrointestinal surgery · 2021
    Review
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Valentyna KryklyvaFrom the Department of Pathology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen.
Esther Ter LindenDepartment of Pathology, University Medical Center Utrecht, Utrecht University, Utrecht.
Leonie I KroezeFrom the Department of Pathology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen.
Richarda M de VoerDepartments of Human Genetics.
B Marion van der KolkSurgery.
Martijn W J StommelSurgery.
John J HermansRadiology and Nuclear Medicine, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences/Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
Claudio LuchiniSection of Pathology, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
Laura D WoodDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD.
Ralph H HrubanDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD.
Iris D NagtegaalFrom the Department of Pathology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen.
Marjolijn J L Ligtenberg
Lodewijk A A Brosens

Funding

Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI JAFFEE, ELIZABETH M. · 1993 to 2022
$54.6M
NCI NIH HHS P50 CA062924
6 · The paper itself

Abstract

Medullary pancreatic carcinoma (MPC) is a rare histological variant of pancreatic ductal adenocarcinoma (PDAC). Because of its rarity, data on the molecular background of MPC are limited. Previous studies have shown that a subset of MPCs is microsatellite instable due to mismatch repair deficiency. Here, we present a unique case of a female patient in her 60s who is a long-term survivor after surgery for pancreatic cancer. The patient had a microsatellite stable MPC with a somatic mutation of the polymerase epsilon gene (POLE). Both microsatellite instable and POLE-mutated cancers are usually associated with high tumor mutational burden and antigen load, resulting in a prominent antitumor immune response and overall better survival. The current case illustrates that, in addition to mismatch repair deficiency, MPC can develop because of a somatic POLE mutation, resulting in a tumor with a high tumor mutational burden and leading to a better prognosis compared with conventional PDAC. This new finding may have important implications in the management of patients with MPC and calls for further studies on the role of POLE in PDAC.

Indexed as

MutationCancer SurvivorsCarcinoma, Pancreatic DuctalDNA Polymerase IIFemaleGenetic Predisposition to DiseaseHumansKeratin-7Magnetic Resonance ImagingMiddle AgedPancreatic NeoplasmsPoly-ADP-Ribose Binding ProteinsSurvival AnalysisDNA Polymerase IIKeratin-7POLE protein, humanPoly-ADP-Ribose Binding Proteins

Identifiers

PMID32658072
PMCPMC7368848

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.